Navigation Links
Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements
Date:1/12/2009

mpany's NASDAQ listing to continue or for how long such listing will continue. If the Company is unsuccessful in maintaining its NASDAQ listing, then the Company may pursue listing and trading of the Company's common stock on the Over-The-Counter Bulletin Board or another securities exchange or association with different listing standards than NASDAQ.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
2. Alseres Pharmaceuticals, Inc. Raises $5 Million
3. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
4. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
5. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
6. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
7. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
8. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
9. Alseres Pharmaceuticals, Inc.s Chairman, Peter Savas, Reviews Companys Progress in its Annual Letter to Stockholders
10. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
11. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... CA (PRWEB) November 21, 2014 ... creating picture-perfect smiles for patients in preparation for the ... to the fronts of teeth, look completely natural, and ... certain situations, veneers are also valued for their ability ... patients and can be used on one or several ...
(Date:11/21/2014)... 2014 (HealthDay News) -- The cost of diabetes care ... recent years, climbing to more than $322 billion annually, ... cost were seen with prediabetes care, which have risen ... percent, the researchers added. In 2012, excess medical ... than $1,000 for every American. That total includes $244 ...
(Date:11/21/2014)... November 21, 2014 Richard Wolfe, ... , will present advanced benefits administration strategies during ... Houston HR Leadership Summit. This Game Changer breakout ... industry to present cutting-edge solutions and best practices ... explain how real-time data exchange between health and ...
(Date:11/21/2014)... Saint Luke’s Mid America Heart ... Failure Gold-Plus Quality Achievement Award for implementing specific ... Association/American College of Cardiology Foundation in their secondary ... With The Guidelines–Heart Failure is a quality improvement ... up-to-date, research-based guidelines with the goal of speeding ...
(Date:11/21/2014)... November 21, 2014 The typical Thanksgiving ... calorie dishes, plenty of gravy and a myriad of ... the best time of year to begin losing weight? ... has uncovered the secret to losing unhealthy, embarrassing and ... holiday recipes. , The insight to Diet Doc’s calorie ...
Breaking Medicine News(10 mins):Health News:Los Angeles Porcelain Veneers Dentist, Dr. Kevin Sands, Now Creates Picture-Perfect Smiles for Patients for the Holiday Season 2Health News:Cost of Diabetes Care Keeps Climbing, Report Shows 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 3Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 3Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 4Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 2Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 3Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 4
... in this group , WEDNESDAY, June 2 (HealthDay News) -- ... of developing prostate cancer than white men, but now a ... likely to develop aggressive forms of the disease. , Researchers ... whites -- whose prostates were removed at the Durham Veterans ...
... ... maker of the life’sDHA™ brand, Martek Biosciences Corporation (NASDAQ: MATK) announced today that Norman ... selected as the recipient of the Alex Leaf Distinguished Scientist Award for 2010. ... Columbia, Md. (Vocus) ...
... ... in the last several years. ,Global Launch Management, a product launch management company, offers ... traditional marketing, the product launch marketing model has been very successful for many 60 ... ...
... say , WEDNESDAY, June 2 (HealthDay News) -- A ... for a kind of brain tumor in children, researchers report. ... 20 percent of childhood brain cancer cases. Treatment, which can ... at five years to 70 percent, but the tumors remain ...
... donations have more than doubled since the institution of grassroots ... published in the May issue of the Journal of ... of minority donors is expected to reach 35 percent, up ... organ transplant in 1954, the shortage of organ donors has ...
... reporting new evidence that capsaicin, the stuff that gives chili ... buildup by triggering certain beneficial protein changes in the body. ... appears in ACS, monthly Journal of Proteome Research . ... obesity is a major public health threat worldwide, linked to ...
Cached Medicine News:Health News:Martek Biosciences Chief Scientific Officer, Dr. Norman Salem, 2010 Recipient of ,Alex Leaf Distinguished Scientist Award 2Health News:Martek Biosciences Chief Scientific Officer, Dr. Norman Salem, 2010 Recipient of ,Alex Leaf Distinguished Scientist Award 3Health News:Traditional Marketing is Dead! GLM Creates a Sales Spike in Under 60 Days Stops Business Failure; Provides Startup Funding 2Health News:Grassroots programs to encourage minority organ donation prove successful 2
(Date:11/21/2014)... EVANSTON, Ill. , Nov. 21, 2014  Heated ... prescription drug prices – from cancer treatments to Gilead,s ... and pharmaceutical leaders around the world questioning what it ... quality of care. And while drug ... the pharmaceutical industry – from both a general business ...
(Date:11/21/2014)... Clementia Pharmaceuticals, Inc.  announced ... has granted Orphan Medicinal Product Designation for ... the treatment of fibrodysplasia ossificans progressiva (FOP). ... disease characterized by painful, recurrent episodes of ... bone formation. This process, known as heterotopic ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Chief Executive Officer, will be presenting at the 26 th ... Palace Hotel in New York . The ... 2:00 PM ET. In addition, Mr. Krakauer and Jorgen ... separate one-on-one meetings during the day. An ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
... - IgG1 monoclonal,antibodies developed by ImClone Systems ... total presentations at the recently concluded,98th Annual ... Research,(AACR), including seven oral presentations and 37 ... the focus of,two back-to-back oral presentations leading ...
... ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis ... discussed results from two pre-clinical studies ... and,rationale for combining nab-paclitaxel (ABRAXANE(R) for ... (albumin-bound)) with VEGF inhibitor drugs like,bevacizumab ...
Cached Medicine Technology:ImClone Systems Showcases Extensive Research and Development,Program at the AACR Annual Meeting 2ImClone Systems Showcases Extensive Research and Development,Program at the AACR Annual Meeting 3ImClone Systems Showcases Extensive Research and Development,Program at the AACR Annual Meeting 4ImClone Systems Showcases Extensive Research and Development,Program at the AACR Annual Meeting 5Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: